Moberg Pharma AB Interim report January - March 2021
REGISTRATION PREPARATIONS FULLY UNDERWAYFIRST QUARTER (JAN-MAR 2021) · EBITDA SEK -5.4 million (-3.6) * · Operating profit (EBIT) SEK -6.1 million (-4.2) * · Profit after tax SEK -5.0 million (-3.4) * · Total profit SEK 18.6 million (-3.4) · Diluted earnings per share SEK 0.46 (-0.18) * · Cash and cash equivalents amounted to SEK 133.6 million (51.6) · Cash and cash equivalents SEK 142 million adjusted for effects of OncoZenge divestment (reversed in Q2) * All comparative figures refer to continuing operations SIGNIFICANT EVENTS IN THE FIRST QUARTER · A